SCHEMBL6303723

SCHEMBL6303723

Fc1ccc(NC(=S)NC2CCCC2N2CCC(Cc3ccc(Cl)cc3)CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ NPSR1 Q6W5P4 3/20 0.45
▸ GMNN O75496 1/20 0.45
▸ TP53 P04637 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ ALOX15 P16050 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ NFKB1 P19838 1/20 0.45
▸ THPO P40225 1/20 0.45
▸ MTOR P42345 1/20 0.45
▸ BLM P54132 1/20 0.45
▸ GRIN1 Q05586 1/20 0.45
▸ GRIN2B Q13224 1/20 0.45
▸ MAPT P10636 4/20 0.45
▸ LMNA P02545 3/20 0.45
▸ ALOX12 P18054 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6303726 1.00 SMN1; SMN2 (0.46) SMN1; SMN2KMT2AMEN1GAANPSR1
SCHEMBL6303831 0.90 POLB (0.44) SMN1; SMN2KMT2AMEN1GAANPSR1
SCHEMBL6303829 0.90 POLB (0.44) SMN1; SMN2KMT2AMEN1GAANPSR1
SCHEMBL6303570 0.88 CCR3 (0.55) POLBCCR3
SCHEMBL6303572 0.88 CCR3 (0.55) POLBCCR3
SCHEMBL6303712 0.87 KMT2A (0.46) SMN1; SMN2KMT2AMEN1GAAMAPT
SCHEMBL6303713 0.87 KMT2A (0.46) SMN1; SMN2KMT2AMEN1GAAMAPT
SCHEMBL6303668 0.85 KMT2A (0.49) KMT2AMEN1CYP3A4MAPTLMNA
SCHEMBL6304204 0.83 FAAH (0.48) SMN1; SMN2KMT2AMEN1MAPTLMNA
SCHEMBL6304207 0.83 FAAH (0.48) SMN1; SMN2KMT2AMEN1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6977265-B2 Piperidine CCR-3 receptor antagonists ROCHE PALO ALTO LLC (US) 2005-12-20 — — US disclosed
EP-1453825-A1 N-UREIDO-PIPERIDINES AS ANTAGONISTS VIII FOR CCR-3 RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2004-09-08 — — EP disclosed
US-20030229121-A1 Piperidine CCR-3 receptor antagonists SYNTEX (U.S.A.) LLC 2003-12-11 — — US disclosed
WO-2003045937-A1 N-UREIDO-PIPERIDINES AS ANTAGONISTS VIII FOR CCR-3 RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2003-06-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229121-A1 Piperidine CCR-3 receptor antagonists CCR1, CCR3, CCRL2 SMN1; SMN2 3011/4885KMT2A 3093/4885MEN1 4556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback